Novo Nordisk is a global healthcare company founded in Denmark in 1923 and a leader in diabetes care. The company also focuses on other serious chronic diseases, including obesity, hemophilia, and growth disorders. Driven by a strong sustainability purpose, its therapies help millions of people. Novo Nordisk pioneers biopharmaceuticalinnovation with treatments like insulin and GLP-1 therapies.
Novo Nordisk’s regulatory validation of a once-daily oral semaglutide expands weight-management options in metabolic care and cardiovascular risk reduction.
